In the hyper-competitive biotech arena, Coeptis Therapeutics operates with the stealth of a startup and the ambition of a giant. With just 7 employees and $1.4M in revenue, they are attempting to crack the code on innovative cell therapy platforms for oncology.

"They aren't building a brand for the public; they are building a platform for the future of cancer treatment."

• Clinical-stage focus with a lean operational structure.
• Heavy reliance on direct traffic (42%), indicating a dedicated investor/industry audience.
• WordPress-based tech stack suggests cost-effective, scalable web infrastructure.

The traffic data reveals a telling story. While total visits are low (1,809/month), the 42% direct traffic share is significant for a company of this size. This implies that the people finding Coeptis aren't stumbling upon them via Google; they are typing the URL directly. This is the hallmark of a company with a specific, engaged audience—likely investors and industry partners.